This immunologic setting has yielded in the development of immunotherapeutic treatment regimens in RCC, such as the use of Interleukin-2 (IL-2) or peptide- and ribonucleic acid (RNA)-based vaccination protocols[1–3]. Here, IL2 is linked to renal cell adenocarcinoma.